Estriol combined with glatiramer acetate for women with relapsing-remitting multiple sclerosis: A randomised, placebo-controlled, phase 2 trial

The Lancet Neurology

Volumn 15, Issue 1, 2016, Pages 35-46

  Voskuhl, Rhonda R ^a   Wang, HeJing ^a   Wu, T C Jackson ^a   Sicotte, Nancy L ^b   Nakamura, Kunio ^c   Kurth, Florian ^a   Itoh, Noriko ^a   Bardens, Jenny ^a   Bernard, Jacqueline T ^d   Corboy, John R ^e   Cross, Anne H ^f   Dhib Jalbut, Suhayl ^g   Ford, Corey C ^h   Frohman, Elliot M ⁱ   Giesser, Barbara ^a   Jacobs, Dina ^j   Kasper, Lloyd H ^k   Lynch, Sharon ^l   Parry, Gareth ^m   Racke, Michael K ⁿ   Reder, Anthony T ⁿ   Rose, John ^o   Wingerchuk, Dean M ^p   MacKenzie Graham, Allan J ^a   Arnold, Douglas L ^c   Tseng, Chi Hong ^a   Elashoff, Robert ^a   more..

^a UNIVERSITY OF CALIFORNIA   (United States)

^b CEDARS SINAI MEDICAL CENTER   (United States)

^c MCGILL UNIVERSITY   (Canada)

^d UNIVERSITY OF CHICAGO MEDICAL CENTER   (United States)

^e UNIVERSITY OF COLORADO   (United States)

^f WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g ROBERT WOOD JOHNSON MEDICAL SCHOOL   (United States)

^h UNIVERSITY OF NEW MEXICO HEALTH SCIENCES CENTER   (United States)

ⁱ UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^j UNIVERSITY OF PENNSYLVANIA   (United States)

^k DARTMOUTH MEDICAL SCHOOL   (United States)

^l UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^m UNIVERSITY OF MINNESOTA   (United States)

ⁿ THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

^o VETERANS AFFAIRS MEDICAL CENTER   (United States)

^p MAYO CLINIC   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ESTRIOL; GLATIRAMER; PLACEBO; IMMUNOLOGICAL ADJUVANT;

ACUTE APPENDICITIS; ADULT; ANXIETY DISORDER; ARTICLE; B CELL LYMPHOMA; BACKACHE; CONTROLLED STUDY; CYSTIC FIBROSIS; DEPRESSION; DIZZINESS; DOUBLE BLIND PROCEDURE; DRUG TOLERABILITY; DRUG WITHDRAWAL; DYSPNEA; ENDOMETRIAL THICKNESS; ENDOMETRIUM BIOPSY; EXPANDED DISABILITY STATUS SCALE; EYE PAIN; FATIGUE; FEMALE; FIBROCYSTIC BREAST DISEASE; GASTROENTERITIS; HEADACHE; HEART FAILURE; HEART PALPITATION; HERPES ZOSTER; HOT FLUSH; HUMAN; HUMAN TISSUE; INJECTION SITE REACTION; INSOMNIA; INTENTION TO TREAT ANALYSIS; KNEE REPLACEMENT; MAJOR CLINICAL STUDY; MAMMOGRAPHY; MENSTRUAL IRREGULARITY; MENSTRUATION DISORDER; MIGRAINE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; NAUSEA; PACEMAKER FAILURE; PARESTHESIA; PHASE 2 CLINICAL TRIAL; PREGNANCY TERMINATION; PRIORITY JOURNAL; PYELONEPHRITIS; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RELAPSE; SEDATION; SINUSITIS; SKIN TINGLING; TRAFFIC ACCIDENT; TREATMENT DURATION; TREATMENT OUTCOME; ULTRASOUND; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS MYOMA; VAGINITIS; VISUAL DISORDER; VOMITING; CLINICAL TRIAL; COMBINATION DRUG THERAPY; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

ADJUVANTS, IMMUNOLOGIC; ADULT; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; ESTRIOL; FEMALE; GLATIRAMER ACETATE; HUMANS; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING;

EID: 84965189899     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(15)00322-1     Document Type: Article

References (42)

1. Trojano M, Tortorella C MS and related disorders: looking for markers of phenotypes. Lancet Neurol 2015, 14:11-13.
2. Confavreux C, Hutchinson M, Hours MM, Cortinovis-Tourniaire P, Moreau T Rate of pregnancy-related relapse in multiple sclerosis. Pregnancy in Multiple Sclerosis Group. N Engl J Med 1998, 339:285-291.
3. Lindberg BS, Johansson ED, Nilsson BA Plasma levels of nonconjugated oestrone, oestradiol-17beta and oestriol during uncomplicated pregnancy. Acta Obstet Gynecol Scand Suppl 1974, 32:21-36.
4. Wegmann TG, Lin H, Guilbert L, Mosmann TR Bidirectional cytokine interactions in the maternal-fetal relationship: is successful pregnancy a TH2 phenomenon?. Immunol Today 1993, 14:353-356.
5. Whitacre CC, Reingold SC, O'Looney PA A gender gap in autoimmunity. Science 1999, 283:1277-1278.
6. Spence RD, Voskuhl RR Neuroprotective effects of estrogens and androgens in CNS inflammation and neurodegeneration. Front Neuroendocrinol 2012, 33:105-115.
7. Sicotte NL, Liva SM, Klutch R, et al. Treatment of multiple sclerosis with the pregnancy hormone estriol. Ann Neurol 2002, 52:421-428.
8. Gold SM, Sasidhar MV, Morales LB, et al. Estrogen treatment decreases matrix metalloproteinase (MMP)-9 in autoimmune demyelinating disease through estrogen receptor alpha (ERalpha). Lab Invest 2009, 89:1076-1083.
9. Soldan SS, Retuerto AI, Sicotte NL, Voskuhl RR Immune modulation in multiple sclerosis patients treated with the pregnancy hormone estriol. J Immunol 2003, 171:6267-6274.
10. Brinton LA, Lacey JV, Trimble EL Hormones and endometrial cancer-new data from the Million Women Study. Lancet 2005, 365:1517-1518.
11. Granberg S, Eurenius K, Lindgren R, Wilhelmsson L The effects of oral estriol on the endometrium in postmenopausal women. Maturitas 2002, 42:149-156.
12. Lauritzen C Results of a 5 years prospective study of estriol succinate treatment in patients with climacteric complaints. Horm Metab Res 1987, 19:579-584.
13. Takahashi K, Manabe A, Okada M, Kurioka H, Kanasaki H, Miyazaki K Efficacy and safety of oral estriol for managing postmenopausal symptoms. Maturitas 2000, 34:169-177.
14. Rossouw JE, Anderson GL, Prentice RL Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial. JAMA 2002, 288:321-333.
15. Marchbanks PA, McDonald JA, Wilson HG, et al. Oral contraceptives and the risk of breast cancer. N Engl J Med 2002, 346:2025-2032.
16. Eckler K Are all estrogens created equal?. Menopause 2004, 11:7-8.
17. Enmark E, Gustafsson JA Oestrogen receptors - an overview. J Intern Med 1999, 246:133-138.
18. Lemon HM Oestriol and prevention of breast cancer. Lancet 1973, 1:546-547.
19. Weiss NS, Sayvetz TA Incidence of endometrial cancer in relation to the use of oral contraceptives. N Engl J Med 1980, 302:551-554.
20. Polman CH, Reingold SC, Banwell B, et al. Diagnostic criteria for multiple sclerosis: 2010 revisions to the McDonald criteria. Ann Neurol 2011, 69:292-302.
21. Zelen M The randomization and stratification of patients to clinical trials. J Chronic Dis 1974, 27:365-375.
22. Nakamura K, Guizard N, Fonov VS, Narayanan S, Collins DL, Arnold DL Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. Neuroimage Clin 2014, 4:10-17.
23. Nakamura K, Guizard N, Fonov VS, Narayanan S, Collins DL, Arnold DL Jacobian integration method increases the statistical power to measure gray matter atrophy in multiple sclerosis. Neuroimage Clin 2013, 4:10-17.
24. Kurth F, Luders E, Sicotte NL, et al. Neuroprotective effects of testosterone treatment in men with multiple sclerosis. Neuroimage Clin 2014, 4:454-460.
25. Jacobs LD, Cookfair DL, Rudick RA, et al. Intramuscular interferon beta-1a for disease progression in relapsing multiple sclerosis. The Multiple Sclerosis Collaborative Research Group (MSCRG). Ann Neurol 1996, 39:285-294.
26. Comi G, Filippi M, Wolinsky JS European/Canadian multicenter, double-blind, randomized, placebo-controlled study of the effects of glatiramer acetate on magnetic resonance imaging-measured disease activity and burden in patients with relapsing multiple sclerosis. European/Canadian Glatiramer Acetate Study Group. Ann Neurol 2001, 49:290-297.
27. Rubinstein LV, Korn EL, Freidlin B, Hunsberger S, Ivy SP, Smith MA Design issues of randomized phase II trials and a proposal for phase II screening trials. J Clin Oncol 2005, 23:7199-7206.
28. Palesch YY, Tilley BC, Sackett DL, Johnston KC, Woolson R Applying a phase II futility study design to therapeutic stroke trials. Stroke 2005, 36:2410-2414.
29. Miller RG, Block G, Katz JS, et al. Randomized phase 2 trial of NP001-a novel immune regulator: Safety and early efficacy in ALS. Neurol Neuroimmunol Neuroinflamm 2015, 2:e100.
30. Elm JJ, Goetz CG, Ravina B, et al. A responsive outcome for Parkinson's disease neuroprotection futility studies. Ann Neurol 2005, 57:197-203.
31. Vickrey BG, Hays RD, Harooni R, Myers LW, Ellison GW A health-related quality of life measure for multiple sclerosis. Qual Life Res 1995, 4:187-206.
32. Brandberg A, Mellstrom D, Samsioe G Low dose oral estriol treatment in elderly women with urogenital infections. Acta Obstet Gynecol Scand Suppl 1987, 140:33-38.
33. Raz R, Stamm WE A controlled trial of intravaginal estriol in postmenopausal women with recurrent urinary tract infections. N Engl J Med 1993, 329:753-776.
34. Amato MP, Portaccio E, Goretti B, et al. Association of neocortical volume changes with cognitive deterioration in relapsing-remitting multiple sclerosis. Arch Neurol 2007, 64:1157-1161.
35. Sbardella E, Petsas N, Tona F, et al. Assessing the correlation between grey and white matter damage with motor and cognitive impairment in multiple sclerosis patients. PLoS One 2013, 8:e63250.
36. Verghese J, Kuslansky G, Katz MJ, et al. Cognitive performance in surgically menopausal women on estrogen. Neurology 2000, 55:872-874.
37. Kramar EA, Babayan AH, Gall CM, Lynch G Estrogen promotes learning-related plasticity by modifying the synaptic cytoskeleton. Neuroscience 2013, 239:3-16.
38. Smejkalova T, Woolley CS Estradiol acutely potentiates hippocampal excitatory synaptic transmission through a presynaptic mechanism. J Neurosci 2010, 30:16137-16148.
39. Ziehn MO, Avedisian AA, Dervin SM, O'Dell TJ, Voskuhl RR Estriol preserves synaptic transmission in the hippocampus during autoimmune demyelinating disease. Lab Invest 2012, 92:1234-1245.
40. Zivadinov R, Reder AT, Filippi M, et al. Mechanisms of action of disease-modifying agents and brain volume changes in multiple sclerosis. Neurology 2008, 71:136-144.
41. Nixon R, Bergvall N, Tomic D, Sfikas N, Cutter G, Giovannoni G No evidence of disease activity: indirect comparisons of oral therapies for the treatment of relapsing-remitting multiple sclerosis. Adv Ther 2014, 31:1134-1154.
42. Stuve O, Cutter GR Multiple sclerosis drugs: how much bang for the buck?. Lancet Neurol 2015, 14:460-461.